Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
Brief Summary: The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer


Options:
A: Inclusion Criteria:

* Histological confirmed diagnosis of relapsed intracranial GB
* Progressive Disease (PD) following standard chemoradiation
* Prior surgical resection allowed
* Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1
* Adequate hematologic, hepatic and renal function
* Discontinued all prior cancer treatments for cancer \& recovered from the acute effects of therapy
* Tumor specimen must be available for a central pathology review and prognostic and predictive biomarker evaluation

Exclusion Criteria:

* Moderate or severe heart disease based on New York Heart Association (NYHA) criteria
* Prior nitrosurea therapy (including lomustine or Gliadel)
* Prior bevacizumab as 1st line treatment for GB (if treatment was concluded 12 months prior to enrollment, the patient may be eligible to participate in the trial)
* Current acute or chronic myelogenous leukemia
* Second primary malignancy that may affect the interpretation of results
* Serious concomitant systemic disorder
B: Inclusion Criteria at Enrollment (before PD1):

* Newly diagnosed, histologically confirmed glioblastoma not previously treated with chemotherapy or radiotherapy
* If female and not postmenopausal (less than \[\<\] 12 months of amenorrhea) or surgically sterile, must agree to use a highly effective contraceptive method during the treatment period and for at least 6 months after the last dose of study drug
* Karnofsky performance status (KPS) greater than or equal to (\>/=) 60
* Mandatory tissue collection during pre-study surgery or biopsy for confirmation of the diagnosis and pathology
* Craniotomy or intracranial biopsy site must be adequately healed. Study treatment should be initiated \> 28 days following the last surgical procedure

Inclusion Criteria at Randomization (following PD1):

* Documented PD1 according to RANO criteria
* Eligibility for second-line treatment with lomustine and bevacizumab as investigational medicinal products
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Bevacizumab well tolerated and not interrupted for longer than 60 days during first-line treatment
* Tissue submission among participants for whom operation/re-operation is indicated before second-line treatment starts; operation/re-operation performed \>/=28 days after last bevacizumab administration and second-line treatment initiated \>/=28 days after surgical wound healed
* Randomization within 28 days after PD1 among participants for whom operation/re-operation is not necessary
* First administration of second-line treatment no later than 2 days from randomization

Exclusion Criteria at Enrollment (before PD1):

* Any prior chemotherapy for glioblastoma and low-grade astrocytomas
* Any prior radiotherapy to the brain or prior radiotherapy resulting in a potential overlap in the radiation field
* Prior or current anti-angiogenic treatment
* Treatment with any other investigational drug within 28 days or 2 investigational agent half-lives (whichever is longer) prior to first study treatment
* Inadequate hematological, renal, or liver function
* Inadequately controlled hypertension
* Prior history of gastrointestinal perforation or abscess
* Clinically significant cardiovascular disease
* History or evidence of central nervous system disease unrelated to cancer unless adequately treated with standard medical therapy
* History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding
* Serious non-healing wound, active ulcer, or untreated bone fracture
* Known hypersensitivity to any component of bevacizumab/placebo or any of the study drugs
* Active infection requiring IV antibiotics at start of study treatment
* Other malignancy within 5 years prior to study enrollment, except for carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ treated with curative intent
* Pregnant or lactating women
* Participation in any other study
C: Inclusion Criteria:

* Histologically confirmed WHO grades 3 to 4 malignant glioma
* Diagnosed recurrence or progression by clinical or radiological evidence
* Fit for intraarterial infusion and intravenous chemotherapy
* Adequate hepatic, renal, and hematologic function.
* Legal age ≥18 years
* Life expectancy ≥12 weeks
* Eastern Cooperative Oncology Group performance (ECOG) ≥2
* Chemotherapy completion ≥4 weeks prior and recovery from drug induced toxicities.

Exclusion Criteria:

* Active pregnancy
* Prior gene therapy
* Second primary tumor
* Gravidity, lactation, hypersensitivity to antiviral drugs, immunologic deficit, active uncontrolled infections
* Requiring treatment with warfarin or any other anticoagulants
D: Inclusion Criteria:

* Unifocal, supratentorial recurrent glioblastoma
* Prior course of standard treatment
* Complete resection of all contrast enhancing areas
* age ≥ 18 years of age
* Karnofsky Performance Score 60% or higher
* For women with childbearing potential, (and men) adequate contraception.
* Ability of subject to understand character and individual consequences of the clinical trial
* Written informed consent (must be available before enrolment in the trial)

Exclusion Criteria:

* Multifocal glioblastoma of gliomatosis cerebri
* Time interval of less than 6 months after primary radiotherapy
* Previous re-irradiation or prior radiosurgery of prior treatment with interstitial radioactive seeds
* refusal of the patients to take part in the study
* Patients who have not yet recovered from acute toxicities of prior therapies
* Known carcinoma \< 5 years ago (excluding Carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy
* Pregnant or lactating women
* Participation in another clinical study or observation period of competing trials, respectively.

Answer: A